Atopic dermatitis treatment study for Costa Rica patients
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at how well two types of advanced medications, dupilumab and JAK inhibitors, work for people with moderate-to-severe atopic dermatitis. It helps doctors learn which treatments are most effective in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor's diagnosis of atopic dermatitis (eczema)
- Your eczema is moderate to severe and needs strong treatment
- You are already taking or about to start a biologic medicine or other advanced therapy
- You are being seen at a participating dermatology center in Costa Rica
- Your medical records have enough information about your condition and treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This study compares two types of eczema treatments—upadacitinib and biologics—to see how well they help adults with moderate-to-severe atopic dermatitis achieve minimal disease activity. It may help you understand which treatment option could work best for your eczema.
This study tests whether combining two drugs, dupilumab and tofacitinib, works better for moderate to severe eczema in adults than either alone. It may help people whose eczema is not well controlled with standard treatments.
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.